Back
Akero Therapeutics Vs. Bowman Consulting Group Industry Stock Comparison
Sell
34
AKRO
Akero Therapeutics
Last Price:
19.65
Seasonality Move:
17.5%
Sell
33
BWMN
Bowman Consulting Group
Last Price:
31.84
Seasonality Move:
-0.83%
Sell
34
Akero Therapeutics (AKRO)
is a Sell
Is Akero Therapeutics a Buy, Sell or Hold?
- The current Akero Therapeutics [AKRO] share price is $19.65. The Score for AKRO is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.
- AKRO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
33
Bowman Consulting Group (BWMN)
is a Sell
Is Bowman Consulting Group a Buy, Sell or Hold?
- The current Bowman Consulting Group [BWMN] share price is $31.81. The Score for BWMN is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.
- BWMN is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AKRO Stock Price Chart
What is Akero Therapeutics's stock price today?
-
The Akero Therapeutics share price today is $19.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and AKRO is experiencing selling pressure, which indicates risk of future bearish movement.
BWMN Stock Price Chart
What is Bowman Consulting Group's stock price today?
-
The Bowman Consulting Group share price today is $31.81
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BWMN is experiencing slight selling pressure.
AKRO Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.69 | Sell |
Relative Strength Index (14 RSI): | 39.39 | Sell |
Chaikin Money Flow: | -530509 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (19.8 - 22.16) | Sell |
Bollinger Bands (100): | (20.24 - 26.04) | Sell |
BWMN Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.42 | Sell |
Relative Strength Index (14 RSI): | 47.49 | Sell |
Chaikin Money Flow: | -21670 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (30.6 - 32.6) | Buy |
Bollinger Bands (100): | (30.81 - 36.55) | Sell |
AKRO Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 20.63 | Sell |
20-day SMA: | 20.59 | Sell |
50-day SMA: | 23.81 | Sell |
200-day SMA: | 27.64 | Sell |
8-day EMA: | 20.57 | Sell |
20-day EMA: | 20.99 | Sell |
50-day EMA: | 22.23 | Sell |
200-day EMA: | 26.78 | Sell |
BWMN Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 31.6 | Buy |
20-day SMA: | 31.47 | Buy |
50-day SMA: | 34.06 | Sell |
200-day SMA: | 31.54 | Buy |
8-day EMA: | 31.9 | Sell |
20-day EMA: | 32.06 | Sell |
50-day EMA: | 32.94 | Sell |
200-day EMA: | 31.6 | Buy |
Akero Therapeutics Earnings Growth & AKRO Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.31 per share, a decrease next quarter of $0.06 per share, a decrease this year of $1.16 per share, and a decrease next year of $0.35 per share.
Bowman Consulting Group Earnings Growth & BWMN Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.46 per share, a decrease next quarter of $0.01 per share, an increase this year of $0.66 per share, and an increase next year of $0.34 per share.
Akero Therapeutics Technical Analysis
Apr 29 | Apr 30 | May 1 | May 2 | May 3 | May 6 | May 7 | May 8 | May 9 | May 10 | |
---|---|---|---|---|---|---|---|---|---|---|
Apr | May | |||||||||
29 | 30 | 01 | 02 | 03 | 06 | 07 | 08 | 09 | 10 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Bowman Consulting Group Technical Analysis
Apr 29 | Apr 30 | May 1 | May 2 | May 3 | May 6 | May 7 | May 8 | May 9 | May 10 | |
---|---|---|---|---|---|---|---|---|---|---|
Apr | May | |||||||||
29 | 30 | 01 | 02 | 03 | 06 | 07 | 08 | 09 | 10 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |